

# Guiding diffusion models for antibody sequence and structure co-design with developability properties

Amelia Villegas-Morcillo, Jana M. Weber, and Marcel J.T. Reinders

Pattern Recognition & Bioinformatics, Dept. of Intelligent Systems, EEMCS, TU Delft, Netherlands




Contact: [a.o.villegasmorcillo@tudelft.nl](mailto:a.o.villegasmorcillo@tudelft.nl)




## Antibody structure and composition

**Antibodies** are Y-shaped proteins produced by the immune system in response to pathogens called **antigens**, composed of two **heavy** and two **light chains**, with a **constant** and **variable region**. The antigen-binding site includes six **complementarity-determining regions (CDRs)** denoted as {H1, H2, H3, L1, L2, L3}. CDRs are **highly variable** domains (especially CDR-H3) and determine the **specificity** of an antibody for a particular antigen.




## Antibody design guided on properties



### Property-aware prior

Sample from prior:  $s_j^T \sim \text{Multinomial}(\bar{p})$   
 $= (1 - b) \cdot \text{Uniform}(20) + b \cdot \text{Multinomial}(\bar{p})$   
 Property: **Hydropathy** (proxy for solubility)




### Sampling by property

At each generation timestep:  
 1. Sample  $N$  times  
 2. Select the sample with min. property value  
 With multiple properties, select Pareto optimal  
 Properties: **Hydropathy** and **folding energy** (predicted  $\Delta\Delta G$ )


**No retraining required!**

## Changes in amino acid composition




## Pareto optimal solutions


Guided approaches exhibit a trend towards the **lowest values of hydropathy and predicted  $\Delta\Delta G$** , (a) before and (b) after Rosetta relaxation.



For designs in the Pareto frontier, different CDR sequences lead to **similar structures** compared to the reference, but with **improved hydropathy and predicted  $\Delta\Delta G$** .




## Developing therapeutic antibodies



Developability properties are needed to **ensure manufacturability and clinical use**. **Poor developability profiles** may prevent an antibody from becoming a therapeutic.

## Diffusion model for antibody design

Prior DiffAb model for antibody sequence-structure co-design




**Inputs** for amino acid  $j$ :

- Amino acid types ( $s_j$ )
- $C_\alpha$  atom positions ( $x_j$ )
- Amino acid orientations ( $O_j$ )

Generate **one CDR loop**,  $R = \{(s_j, x_j, O_j) \mid j = l + 1, \dots, l + m\}$ , given the **antibody-antigen complex**,  $C = \{(s_i, x_i, O_i) \mid i \neq j\}$ .

$T = 100$  timesteps of generation

## Guidance on properties is effective



- Sampling by  $\Delta\Delta G$  improves the hydropathy score, sampling by hydropathy improves the pred.  $\Delta\Delta G$ .
- Most favorable outcomes are achieved when **both properties are combined**.
- **AAR (amino acid recovery) and RMSD (root mean square deviation) consistent with unconditioned.**

## References

- J. Kim, et al. "Computational and artificial intelligence-based methods for antibody development." *Trends in Pharmacological Sciences*, 2023.
- S. Luo, et al. "Antigen-specific antibody design and optimization with diffusion-based generative models." In *NeurIPS 2022*.
- J. Kyte and R.F. Doolittle. "A simple method for displaying the hydropathic character of a protein." *Journal of Molecular Biology*, 1982.
- S. Shan, et al. "Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization." *Proceedings of the National Academy of Sciences*, 2022.
- R.F. Alford, et al. "The rosetta all-atom energy function for macromolecular modeling and design." *Journal of chemical theory and computation*, 2017.